Cold Allodynia Pain Model in Cynomolgus Monkeys | Prisys Biotechnologies

Prisys Biotechnologies, a leading preclinical CRO specializing in non-human primate (NHP) pharmacology, has successfully validated a cold-water tail-flick (TFL) model in cynomolgus monkeys. This refined platform provides a sensitive and reproducible method for assessing analgesic efficacy in both normal and pathological pain states-offering strong translational potential for drug discovery targeting neuropathic and cold allodynia pain.

Model Overview

Pain perception in primates shares key physiological and behavioral similarities with humans, making NHP-based pain models invaluable for bridging preclinical and clinical findings. Prisys' cold pain model utilizes controlled cold stimuli to evaluate nociceptive withdrawal latency, allowing researchers to quantify the modulation of pain thresholds following therapeutic interventions.

By combining behavioral analysis with pharmacokinetic and pharmacodynamic correlation, the model enables mechanistic insight into analgesic action and provides a robust foundation for candidate evaluation in the early stages of pain drug development.

Key Advantages

• Clinically Relevant Translation: Accurately reflects human cold hypersensitivity responses, enhancing predictability of clinical outcomes.
• Validated and Reproducible: Optimized cold stimulus conditions ensure consistent and stable responses across studies.
• Ethically Refined Procedures: Monkeys undergo positive reinforcement training and gentle acclimation to minimize stress and ensure animal welfare.
• Flexible Research Integration: Compatible with EEG, fMRI, and nerve conduction assessments for multimodal pain characterization.
• Comprehensive Support: Full-service preclinical package including hematology, clinical chemistry, and behavioral monitoring.

Prisys' validated NHP cold pain model provides a predictive and ethically responsible approach to investigate novel analgesics, including non-opioid candidates targeting peripheral and central pain pathways. The model has demonstrated reliable sensitivity to pharmacological modulation, enabling researchers to evaluate efficacy in both normal and drug-induced pain states.

This platform offers pharmaceutical companies and academic teams a powerful translational tool to de-risk clinical candidates for neuropathic pain, chemotherapy-induced cold allodynia, and other chronic pain disorders.

Accelerate Your Analgesic Research
Partner with Prisys Biotechnologies to explore our advanced NHP pain model systems and customized preclinical solutions.

👉 Contact Prisys Biotechnologies | Advancing Pain Research with Translational NHP Models